Nuvation Bio posted revenue of USD 31.69 million for the quarter ended June 30, 2026, up 555.58% year over year.
Product revenue climbed to USD 23.19 million from USD 1.24 million; collaboration and license agreements revenue rose to USD 8.5 million from USD 3.6 million.
Total costs and expenses increased 20.9% to USD 82.72 million, led by selling, general and administrative expense of USD 42.59 million and R&D of USD 30.66 million.
Other expense widened to USD 11.8 million from other income of USD 4.58 million, driven by a USD 9.47 million loss on debt extinguishment.
Completed a USD 287.5 million offering of 0.75% Convertible Senior Notes due 2032, with net proceeds of about USD 279.1 million.
NUVB•
